TOP
Events & Outreach
R-CCS Cafe
The 229th R-CCS Cafe - part 1
The 229th R-CCS Cafe - part 1
JapaneseTitle
Development of Structure-Based de Novo Molecular Generator (SBMolGen)
Date | Fri, Mar 11, 2022 |
---|---|
Time | 4:00 pm - 4:20 pm (5 pm - 5:20 pm Discussion, 5:20 pm - Free discussion (optional)) |
City | Online |
Place | Online seminar on BlueJeans
|
Language | Presentation Language: English Presentation Material: English |
Speakers |
Biao Ma Research Scientist, Biomedical Computational Intelligence Unit ![]() |
Abstract
Although molecular generation models based on deep learning have attracted significant attention in drug discovery, most existing models have a limitation in the context of drug design wherein they do not sufficiently consider the effect of the three-dimensional (3D) structure of the target protein in the generation process. In this talk, we introduce a novel de novo molecular design method, SBMolGen, which uses the docking score as a reward function to generate high-affinity score compounds for a specified target. More specifically, this deep learning-based molecular generator integrates a recurrent neural network, Monte Carlo tree search, and docking simulations. SBMolGen not only generates novel binding active molecules but also presents 3D docking poses with target proteins, which will be useful in subsequent drug design. The code is available at https://github.com/clinfo/SBMolGen.
Important Notes
- Please turn off your video and microphone when you join the meeting.
- The broadcasting may be interrupted or terminated depending on the network condition or any other unexpected event.
- The program schedule and contents may be modified without prior notice.
- Depending on the utilized device and network environment, it may not be able to watch the session.
- All rights concerning the broadcasted material will belong to the organizer and the presenters, and it is prohibited to copy, modify, or redistribute the total or a part of the broadcasted material without the previous permission of RIKEN.
(Mar 8, 2022)